MARKET INTRODUCTION

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

MARKET DYNAMICS

Hemophilia treatment market is forecasted to grow due to key driving factors such as increasing incidences of blood disorders, rising research and development activities in the pharmaceutical industry, growing awareness programs, and others. The market is expected to have growth opportunities in the developing regions as the pharmaceutical industry is growing significantly.

MARKET SCOPE

The "Global Hemophilia Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of hemophilia treatment market with detailed market segmentation by product, disease, treatment type, therapy, end user and geography. The global hemophilia treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading hemophilia treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global hemophilia treatment market is segmented on the basis of product, disease, treatment type, therapy, and end user. Based on the product the market is segmented as plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytic agents. On the basis of diseases the market is classified as hemophilia A, hemophilia B, and hemophilia C. Based on treatment type the market is divided into on-demand, and prophylaxis. On the basis of therapy the market is classified as replacement therapy, ITI therapy, and gene therapy. And based on the end user the market is segmented as hospitals, clinics, ambulatory surgical centres, and others.


REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global hemophilia treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The hemophilia treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting hemophilia treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the hemophilia treatment market in these regions.


MARKET PLAYERS

The reports cover key developments in the hemophilia treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from hemophilia treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for hemophilia treatment market in the global market. Below mentioned is the list of few companies engaged in the hemophilia treatment market.

The report also includes the profiles of key hemophilia treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Bayer AG
- Biogen Idec
- Biotest AG
- CSL
- Genentech, Inc.
- Kedrion S.p.A
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi
- Octapharma AG.